Business Context and Reporting Period
This Form 8-K filing by Herbalife Ltd. (Cayman Islands) covers events occurring on December 15, 2004, with the report dated December 20, 2004. The filing announces the company's entry into a material definitive agreement for an initial public offering (IPO) and the election of new directors effective upon listing on the New York Stock Exchange on December 16, 2004.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses on capital structure changes related to the IPO.
- Shares to be Issued: 14,500,000 common shares (par value $0.002 per share).
- Selling Shareholder Portion: 1,000,000 shares included in the aggregate offering.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 2,175,000 additional shares.
- Underwriters: Syndicate jointly led by Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. Incorporated.
Material Changes
The primary material change is the transition from a private entity to a public company via the execution of the Purchase Agreement. This agreement facilitates the sale of the aforementioned shares to the underwriting syndicate. Additionally, the company's board composition changed with the election of three new directors.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It references the complete text of the Purchase Agreement filed as Exhibit 1.1 to Amendment No. 5 to the Form S-1 Registration Statement (File No. 333-119485) for full details.
Director Elections:
- Leroy T. Barnes, Jr.: Elected to the Audit and Corporate Governance and Nominating Committees.
- Richard P. Bermingham: Elected to the Audit and Compensation Committees.
- Peter Maslen: Elected to the Audit and Compensation Committees.
Investor Verification Checklist
- Verify the final offering price per share and total proceeds in the final prospectus (Form S-1 Amendment No. 5).
- Confirm the exact number of shares sold by Selling Shareholders versus the company to assess dilution.
- Review the full text of the Purchase Agreement (Exhibit 1.1) for lock-up periods and underwriting terms.
- Check the New York Stock Exchange listing status and ticker symbol effective December 16, 2004.
- Examine the Form S-1 for historical financial data not included in this 8-K.